Effect of antibiotic use on the efficacy of nivolumab in the treatment of advanced/metastatic non-small cell lung cancer: A meta-analysis

This study evaluates the impact of the use of antibiotics on the effectiveness of nivolumab in the treatment of advanced/metastatic non-small cell lung cancer (NSCLC). A literature search was conducted in various electronic databases to identify studies, which evaluated the impact of antibiotic use...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Huo Geng-wei, Zuo Ran, Song Ying, Chen Wei-dong, Chen Wen-ming, Chong Dao-qun, Zhang Hong-mei, Jia Sha-sha, Chen Peng
Formato:	article
Lenguaje:	EN
Publicado:	De Gruyter 2021
Materias:	non-small cell lung cancer nivolumab antibiotics survival meta-analysis Medicine R
Acceso en línea:	https://doaj.org/article/59ee09264e6d483cb51ffc33423a2a66
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:59ee09264e6d483cb51ffc33423a2a66
record_format	dspace
spelling	oai:doaj.org-article:59ee09264e6d483cb51ffc33423a2a662021-12-05T14:10:54ZEffect of antibiotic use on the efficacy of nivolumab in the treatment of advanced/metastatic non-small cell lung cancer: A meta-analysis2391-546310.1515/med-2021-0272https://doaj.org/article/59ee09264e6d483cb51ffc33423a2a662021-05-01T00:00:00Zhttps://doi.org/10.1515/med-2021-0272https://doaj.org/toc/2391-5463This study evaluates the impact of the use of antibiotics on the effectiveness of nivolumab in the treatment of advanced/metastatic non-small cell lung cancer (NSCLC). A literature search was conducted in various electronic databases to identify studies, which evaluated the impact of antibiotic use on the survival of patients with advanced/metastatic NSCLC who have been treated with nivolumab. Six studies, comprising a total of 787 patients with 37.2% females and of age range 30–90 years, were included in the study. A lack of smoking history was reported in 14.4% of the patients. A meta-analysis was conducted in 678 and 713 patients for PFS and OS, respectively. The pooled HR was 1.95 (95% CI: 1.13–3.37, P = 0.016) for PFS and 2.70 (95% CI: 1.81–4.02, P < 0.001) for OS. Among patients exposed to antibiotics, the median PFS and OS were reduced by 1.6 months (95% CI: 1.5–1.7) and 8.8 months (95% CI: 8.5–9.1), respectively. Our study indicates that, among patients with advanced/metastatic NSCLC, the use of antibiotics with nivolumab led to a decrease in the median OS by more than 8 months. Studying the mechanism of the effect of antibiotics on the efficacy of nivolumab in patients with NSCLC should also be prioritized.Huo Geng-weiZuo RanSong YingChen Wei-dongChen Wen-mingChong Dao-qunZhang Hong-meiJia Sha-shaChen PengDe Gruyterarticlenon-small cell lung cancernivolumabantibioticssurvivalmeta-analysisMedicineRENOpen Medicine, Vol 16, Iss 1, Pp 728-736 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	non-small cell lung cancer nivolumab antibiotics survival meta-analysis Medicine R
spellingShingle	non-small cell lung cancer nivolumab antibiotics survival meta-analysis Medicine R Huo Geng-wei Zuo Ran Song Ying Chen Wei-dong Chen Wen-ming Chong Dao-qun Zhang Hong-mei Jia Sha-sha Chen Peng Effect of antibiotic use on the efficacy of nivolumab in the treatment of advanced/metastatic non-small cell lung cancer: A meta-analysis
description	This study evaluates the impact of the use of antibiotics on the effectiveness of nivolumab in the treatment of advanced/metastatic non-small cell lung cancer (NSCLC). A literature search was conducted in various electronic databases to identify studies, which evaluated the impact of antibiotic use on the survival of patients with advanced/metastatic NSCLC who have been treated with nivolumab. Six studies, comprising a total of 787 patients with 37.2% females and of age range 30–90 years, were included in the study. A lack of smoking history was reported in 14.4% of the patients. A meta-analysis was conducted in 678 and 713 patients for PFS and OS, respectively. The pooled HR was 1.95 (95% CI: 1.13–3.37, P = 0.016) for PFS and 2.70 (95% CI: 1.81–4.02, P < 0.001) for OS. Among patients exposed to antibiotics, the median PFS and OS were reduced by 1.6 months (95% CI: 1.5–1.7) and 8.8 months (95% CI: 8.5–9.1), respectively. Our study indicates that, among patients with advanced/metastatic NSCLC, the use of antibiotics with nivolumab led to a decrease in the median OS by more than 8 months. Studying the mechanism of the effect of antibiotics on the efficacy of nivolumab in patients with NSCLC should also be prioritized.
format	article
author	Huo Geng-wei Zuo Ran Song Ying Chen Wei-dong Chen Wen-ming Chong Dao-qun Zhang Hong-mei Jia Sha-sha Chen Peng
author_facet	Huo Geng-wei Zuo Ran Song Ying Chen Wei-dong Chen Wen-ming Chong Dao-qun Zhang Hong-mei Jia Sha-sha Chen Peng
author_sort	Huo Geng-wei
title	Effect of antibiotic use on the efficacy of nivolumab in the treatment of advanced/metastatic non-small cell lung cancer: A meta-analysis
title_short	Effect of antibiotic use on the efficacy of nivolumab in the treatment of advanced/metastatic non-small cell lung cancer: A meta-analysis
title_full	Effect of antibiotic use on the efficacy of nivolumab in the treatment of advanced/metastatic non-small cell lung cancer: A meta-analysis
title_fullStr	Effect of antibiotic use on the efficacy of nivolumab in the treatment of advanced/metastatic non-small cell lung cancer: A meta-analysis
title_full_unstemmed	Effect of antibiotic use on the efficacy of nivolumab in the treatment of advanced/metastatic non-small cell lung cancer: A meta-analysis
title_sort	effect of antibiotic use on the efficacy of nivolumab in the treatment of advanced/metastatic non-small cell lung cancer: a meta-analysis
publisher	De Gruyter
publishDate	2021
url	https://doaj.org/article/59ee09264e6d483cb51ffc33423a2a66
work_keys_str_mv	AT huogengwei effectofantibioticuseontheefficacyofnivolumabinthetreatmentofadvancedmetastaticnonsmallcelllungcancerametaanalysis AT zuoran effectofantibioticuseontheefficacyofnivolumabinthetreatmentofadvancedmetastaticnonsmallcelllungcancerametaanalysis AT songying effectofantibioticuseontheefficacyofnivolumabinthetreatmentofadvancedmetastaticnonsmallcelllungcancerametaanalysis AT chenweidong effectofantibioticuseontheefficacyofnivolumabinthetreatmentofadvancedmetastaticnonsmallcelllungcancerametaanalysis AT chenwenming effectofantibioticuseontheefficacyofnivolumabinthetreatmentofadvancedmetastaticnonsmallcelllungcancerametaanalysis AT chongdaoqun effectofantibioticuseontheefficacyofnivolumabinthetreatmentofadvancedmetastaticnonsmallcelllungcancerametaanalysis AT zhanghongmei effectofantibioticuseontheefficacyofnivolumabinthetreatmentofadvancedmetastaticnonsmallcelllungcancerametaanalysis AT jiashasha effectofantibioticuseontheefficacyofnivolumabinthetreatmentofadvancedmetastaticnonsmallcelllungcancerametaanalysis AT chenpeng effectofantibioticuseontheefficacyofnivolumabinthetreatmentofadvancedmetastaticnonsmallcelllungcancerametaanalysis
_version_	1718371605463171072

Effect of antibiotic use on the efficacy of nivolumab in the treatment of advanced/metastatic non-small cell lung cancer: A meta-analysis

Ejemplares similares